A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b). In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory (R/R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enroll participants with R/R non-small cell lung cancer (NSCLC) and breast cancer (Part 2b).
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 1 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Dec 10, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- AbbVie
- Interventions being studied
- Drug: ABBV-155; Drug: Paclitaxel; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Has a histologic or cytologic diagnosis of a malignant solid tumor.
- Participants enrolled in Part 2a (monotherapy, dose expansion) must have small cell lung cancer (SCLC) diagnosis; participants enrolled to Part 2b (combination therapy, dose expansion) must have either NSCLC or HR-positive/HER2-negative breast cancer.
- Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- Failure of at least 1 prior systemic chemotherapy including all available standard therapies for participants in the dose-escalation phase (Parts 1a and 1b) including the safety lead-in phase (Japan only).
- All participants with breast cancer for subjects in the dose-expansion phase (Part 2b only) must have the following:
- Locally advanced or metastatic HR-positive/HER2-negative breast cancer after failing cyclin-dependent kinase (CDK)4/6 inhibitor-based therapy.
- HR-positivity and HER-2-negativity should be confirmed based on American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria.
- All participants with non-small cell lung cancer (NSCLC) for participants in the dose-expansion phase (Part 2b only) must have R/R NSCLC after at least 1 line of therapy. Participants with activating mutations in EGFR, ALK/ROS1, BRAF genes, or with positive expression of PD-L1 must have been treated with the appropriate targeted therapies.
- All participants with SCLC in the dose-expansion phase (Part 2a only) must have R/R SCLC from at least 1 line of therapy which includes a platinum-based therapy with or without an anti-PD-1/PD-L1 therapy.
- All participants with either breast cancer or NSCLC must have the following if exposed to prior taxane-based therapy:
- No history of taxane allergy (Part 1b and Part 2b only).
- Disease that has relapsed or progressed at least 2 months after most recent exposure to any taxane-based therapy.
- Available tumor tissue suitable for immunohistochemistry testing.
- Adequate kidney, liver, and hematologic laboratory values as described in the protocol.
- Untreated brain or meningeal metastases (participants with a history of metastases may be eligible based on details described in the protocol).
- Grade 2 or higher peripheral neuropathy (only applies to participants who would receive taxane therapy).
- Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.
- Known active infection of hepatitis B, hepatitis C, or human immunodeficiency virus with exceptions as described in the protocol.
- Recent history (within 6 months) of congestive heart failure (defined in the protocol), ischemic cardiovascular event, cardiac arrhythmia requiring pharmacological or surgical intervention, pericardial effusion, or pericarditis.
- Any history of hypersensitivity to any ingredients of ABBV-155 will be excluded. For combination therapy only (Parts 1b and 2b), no history of serious allergic reaction to any taxane or any ingredients used in taxane formulation (e.g., cremaphor).
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Alabama at Birmingham - Main /ID# 214024Birmingham, Alabama
- Highlands Oncology Group, PA /ID# 201568Springdale, Arkansas
- UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 206105Orange, California
- Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 204267West Hollywood, California
- Univ of Colorado Cancer Center /ID# 208365Aurora, Colorado
- Yale University, Yale Cancer Center /ID# 201542New Haven, Connecticut
- AdventHealth Orlando /ID# 227242Orlando, Florida
- Northwestern University Feinberg School of Medicine /ID# 201563Chicago, Illinois
- Duplicate_Johns Hopkins Bayview Med Cnt /ID# 215095Baltimore, Maryland
- Johns Hopkins Hospital /ID# 201320Baltimore, Maryland
- Dana-Farber Cancer Institute /ID# 201564Boston, Massachusetts
- Duplicate_Henry Ford Hospital /ID# 226852Detroit, Michigan
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 10, 2025. Always confirm current availability with the study team.